Oxford BioTherapeutics

Oxford BioTherapeutics is an international biotechnology company focused on developing innovative antibody therapies to treat cancer. This new treatment approach combines a number of technologies to target cancer cells with potent cell-killing agents. Our OGAP® target discovery system provides a unique range of validated, novel antigen targets identified from a wide range of cancer types. We are now advancing our portfolio of treatments into clinical testing with our development partner Menarini. In addition to this in-house ADC development, we also work with pharmaceutical companies to provide our target discovery expertise as the foundation for new cancer therapies. Company Leadership Christian Rohlff, CEO Scott Sandler, VP, Finance & Operations Tom Boone, VP, Protein Sciences